In this introductory article, we describe the rationale for the Enterics for Global Health (EFGH) Shigella surveillance study, which is largely to optimize the design and implementation of pivotal Shigella vaccine trials in the target population of infants and young children living in low- and middle-income countries. Such optimization will ideally lead to a shorter time to vaccine availability in the target population. We also provide a brief description of the articles included in the supplement.
Journal article
Open forum infectious diseases
03/2024
11
S1 - S5
Enterics, Diagnostics, Genomics & Epidemiology, The Bill & Melinda Gates Foundation, Seattle, Washington, USA.